Rationale Psychoactive "bath salts" represent a relatively new drug of abuse combination that was placed in Schedule I in October 2011. Two common ingredients of bath salts include the cathinone analogs: mephedrone and methylenedioxypyrovalerone (MDPV). The mechanism of action of these synthetic cathinone analogs has not been well investigated. Materials and methods Because cathinone and methcathinone are known to act as releasing agents at the human dopamine transporter (hDAT), mephedrone and MDPV were investigated at hDAT expressed in Xenopus oocytes. Results Whereas mephedrone was found to have the signature of a dopamine-releasing agent similar to methamphetamine or methcathinone, MDPV behaved as a cocaine-like reuptake inhibitor of dopamine. Conclusions Mephedrone and MDPV produce opposite electrophysiological signatures through hDAT expressed in oocytes. Implications are that the combination (as found in bath salts) might produce effects similar to a combination of methamphetamine and cocaine.
Introduction
For centuries, the fresh leaves of the shrub "khat" (i.e., Catha edulis) have been chewed or brewed as a "tea," in the Arabian peninsula and in certain regions of eastern Africa for their central stimulant properties (reviewed: Balint et al. 2009; Kennedy et al. 1980) . Although the plant contains more than 40 different endogenous constituents, the active "stimulant" component of khat was identified as S(−)cathinone (United Nations 1979) or the β-keto analog of the established synthetic psychostimulant amphetamine (Fig. 1) . The 1980s witnessed investigations of the pharmacological actions of racemic cathinone and its individual optical isomers and confirmed its amphetamine-like character (e.g., Glennon and Showalter 1981; Kalix 1980 Kalix , 1984 Kalix , 1992 Kalix , 1996 Kalix and Braeden 1985; Kalix and Glennon 1986 and references therein). Shortly thereafter, the Nmonomethyl analog of cathinone, methcathinone ( Fig. 1) , was described and investigated as the methamphetamine counterpart of cathinone (Glennon et al. 1987) . Both cathinone and methcathinone produced discriminative stimulus effects in rats similar to (+)amphetamine (Glennon et al. 1987 (Glennon et al. , 1995 Glennon and Young 2011) . Methcathinone, as do amphetamine, methamphetamine, and cathinone, produced locomotor stimulation in mice (Glennon and Showalter 1981; Glennon et al. 1987) . In both assays, as with the other three agents, the S-isomer of methcathinone was more potent than its R-enantiomer, and methcathinone was found to be at least as potent as methamphetamine.
S-Methcathinone has been employed as a training drug in drug discrimination studies with rats as subjects; S-methcathinone stimulus generalization occurred to several other central stimulants including amphetamine, methamphetamine, and cocaine, and the S-methcathinone stimulus was potently antagonized by pretreatment of the animals with the dopamine receptor antagonist haloperidol (Young and Glennon 1998) . Consistent with possible involvement of a dopaminergic mechanism, cathinone, and later methcathinone, were shown to behave as dopamine-releasing agents (Glennon et al. 1987; Kalix and Glennon 1986) . Both cathinone and methcathinone now are controlled substances.
In the past few years, a number of new synthetic cathinone and methcathinone analogs have appeared on the clandestine market and have attracted considerable attention (Iversen 2010; Spiller et al. 2011) . Among the more popular of these is a combination of two cathinone analogs: mephedrone and 3,4-methylenedioxypyrovalerone (MDPV) (Fig. 1 ) and other synthetic compounds; the combinations are known as "bath salts" or "psychoactive bath salts". What is of particular concern is that relatively little is known about the molecular targets, the pharmacology, or the mechanism of action of these agents; furthermore, products represented as bath salts might contain additional or other cathinone analogs (Spiller et al. 2011) . The major constituents of bath salts were emergency scheduled (Schedule I) in October 2011 (Federal Register 2011) .
"Amphetamine analogs" (or, more accurately, phenylisopropylamine analogs) do not represent a pharmacologically homogeneous class of agents (reviewed: Glennon and Young 2011) . That is, depending upon their substitution pattern, phenylisopropylamines can act as central stimulants (e.g., amphetamine and methamphetamine), classical hallucinogens [e.g., 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane; 1-(4-bromo-2,5-dimethoxyphenyl)-2-aminopropane], or empathogens [e.g., 1-(4-methoxyphenyl)-2-aminopropane]; some produce a combination of effects [e.g., MDMA ("ecstasy" or 1-(3,4-methylenedioxyphenyl)-2-aminopropane-a CNS stimulant and an empathogen)]. Yet others produce no behavioral effect. Hence, cathinone analogs (or, more correctly, phenylpropanonamines), should be no more pharmacologically homogeneous than their parent phenylisopropylamine counterparts. Although some phenylpropanonamines might produce effects analogous to those of their structurally corresponding phenylisopropylamines (e.g., as already demonstrated with cathinone versus amphetamine and methcathinone versus methamphetamine), this is not always the case for certain other cathinone derivatives (Dal Cason et al. 1997; Glennon et al. 1995) . Thus, we have suggested that individual cathinone analogs (i.e., phenylpropanonamines, also referred to as: β-ketoamphetamines, β-keto-phenylisopropylamines, benzylketoamphetamines, and bk-amphetamines) need to be examined in their own right (Dal Cason et al. 1997) .
When our studies with the components of bath salts began, nothing was known about the pharmacology of mephedrone (see "Discussion" for an updated description of the most recent findings), and very little was known about MDPV. It had been reported that at a dose of 20 mg/kg (i.g.), MDPV increases striatal levels of dopamine in mice, as determined by microdialysis, within 30 to 60 min postadministration; MDPV had no effect on serotonin (5-HT) levels (Fuwa et al. 2007 ). This same single dose of MDPV also increased mouse locomotor behavior to an extent comparable to administration of methamphetamine (Fuwa et al. 2007 ); other doses were not evaluated. As with cathinone and methcathinone, the findings were consistent with what might be expected of a methamphetamine-type stimulant. Consequently, given our prior involvement with cathinone analogs, it was of interest to examine purported constituents of bath salts at the human dopamine transporter (hDAT). Here, we report the acute electrophysiological effects of mephedrone and MDPV alone, as a readout for releaser or blocker, and in a successive application, at hDAT expressed in Xenopus oocytes. S-Methamphetamine and S-methcathinone were examined for comparison.
Materials and methods
Electrophysiological studies Oocytes were harvested and prepared from adult Xenopus laevis females following standard procedures (Iwamoto et al. 2006; Ramsey and DeFelice 2002) . Stage V-VI oocytes were selected for cRNA injection within 24 h of isolation. cRNA was transcribed in the pOTV vector (gift of Mark Sonders, Columbia University) using Ambion mMESSAGE mMACHINE T7 kit (Ambion, Inc., Austin, TX). Each oocyte was injected with 50 nL of 1 μg/μL hDAT cRNA (final amount, 50 ng) (Nanoject Auto Oocyte Injector, Drummond Scientific Co., Broomall, PA) and incubated at 18°C for 4-8 days in Ringers solution supplemented with Na + pyruvate (550 μg/mL), streptomycin (100 μg/mL), tetracycline (50 μg/mL), and 5 % dialyzed horse serum.
A two-electrode voltage clamp technique was employed (Iwamoto et al. 2006; Ramsey and DeFelice 2002) . Electrodes have resistances from 1-5 MΩ. Xenopus oocytes expressing hDAT were voltage-clamped to −60 mV and buffer was gently perfused until a stable baseline was obtained. Then experimental substrates were then perfused until stable currents were obtained for time periods indicated. The extracellular solution contained (in millimolar): 120 NaCl, 7.5 HEPES, 5.4 K + gluconate, 1.2 Ca 2+ gluconate, pH7.4 with KOH.
Materials Mephedrone and 3,4-methylenedioxypyrovalerone (MDPV) were prepared as their hydrochloride salts and purified to homogeneity as previously described (de Durnaga and Sanchez 1929; Köppe et al. 1969, respectively) . S(+)Methamphetamine and S(−)methcathinone, as their hydrochloride salts, were available from a previous investigation (Glennon et al. 1995) and were purified to homogeneity. Cocaine hydrochloride was obtained from the NIDA drug supply program.
Results
Mephedrone At −60 mV, 10 μM S-methamphetamine and S-methcathinone (Fig. 1) produced an inward (depolarizing) current through hDAT; mephedrone produced similar effects under the same conditions (representative tracings are shown in Fig. 2 ). All three agents generated a sustained leak ("shelf") current that persisted long after the drug was removed. The shelf current is defined as the current remaining after external removal of substrate. The shelf current, which has been previously described for S(+)amphetamine (Rodriguez-Menchaca et al. 2012) , is not present for dopamine; in particular, the downward deflection that is stimulated by dopamine at −60 mV returns to baseline after its removal (Fig. 2) . The shelf current produced by S-methcathinone or mephedrone is proportionately larger than that elicited by S-methamphetamine when the shelf is compared with the peak. The persistent leak is a depolarizing current which would, during normal synaptic transmission, increase the probability of synaptic vesicle fusion with the presynaptic membrane. Furthermore, once exposed to methcathinone or mephedrone, the dopaminergic synapse would be expected to respond differently to the next release of dopamine, as shown previously (Rodriguez-Menchaca et al. 2012) . In sum, the existence of a methcathinone-or mephedrone-induced shelf current is consistent with a prolonged release of dopamine at dopaminergic synapses, Dose-response studies were conducted by exposing hDAT-expressing oocytes to various drug concentrations at −60 mV and then measuring peak currents (Fig. 3) . Mephedrone was examined as its racemate because this is the form found on the clandestine market, whereas methamphetamine and methcathinone were examined as their more behaviorally potent S-isomers (Glennon et al. 1995) . The order of potency was S-methcathinone (EC 50 =0.23± 0.03 μM, n = 5) > S-methamphetamine (EC 50 = 0.64 ± 0.15 μM, n≥5)≥mephedrone (EC 50 =0.84±0.14 μM, n= 5). The potency of S-methcathinone vs. S-methamphetamine (p<0.01) or mephedrone (p<0.001) was significantly different, whereas that between S-methamphetamine and mephedrone (p>0.05) was not (one-way ANOVA, Tukey post test, F=6.83, df=14). In terms of efficacy (as measured by peak current relative to dopamine), S-methamphetamine (107±6 %, n≥5) produced a greater effect than S-methcathinone (57±1 %, n=5) (p<0.001) or mephedrone (41±1 %, n=5) (p<0.001), and S-methcathinone produced a greater effect than mephedrone (p<0.05; one-way ANOVA, Tukey post test, F=103, df=14).
MDPV In contrast to methamphetamine, methcathinone or mephedrone, MDPV (10 μM) produced an outward, cocaine-like, hyperpolarizing current at −60 mV which, in actuality, shows inhibition of the endogenous leak current of hDAT (Sonders et al. 1997) . That is, both MDPV and cocaine (examined at six different concentrations ranging from 0.01 to 30 μM; Fig. 4 ) produced similar inhibitory effects, with MDPV producing a greater effect (remaining percentage of dopamine pre-pulse=32.9±1.9 % and 24.6± 0.5 %, respectively, n=5; two-tailed t test: p<0.01, t=4.23, df=8), and were of similar potency (EC 50 =0.33±0.07 μM and 0.30±0.04 μM, respectively, n=5) (p>0.05, t=0.36, df = 8) in the inhibition of hDAT endogenous leak. Following application of mephedrone, MDPV (10 μM) was capable of reversing the effect of mephedrone (10 μM) in the same manner that cocaine reverses the effect of S-methamphetamine and mephedrone; furthermore, it is more efficacious in producing the hyperpolarizing effect/inhibiting the endogenous hDAT leak than cocaine consistent with the results from Fig. 4 (Fig. 5) . Thus, MDPV produces a hyperpolarizing current consistent with hDAT blockade. Figure 6 shows that, in the presence of 5 μM dopamine, MDPV reduced the dopamine-induced current in a concentration-dependent manner. Under comparable conditions, cocaine produced a similar effect (IC 50 =1.9±0.1 μM, n=5). However, except at the highest dose (10 μM), MDPV blockade of the dopamine-induced inward current never reached a steady state within the timeframe of the experiment which made it impossible to obtain an IC 50 value for MDPV. From similar data in cells held at −60 mV, a doseinhibition curve (±SEM) was obtained for cocaine (Fig. 6c) . Each drug concentration was applied in the presence of dopamine (5 μM). Data were obtained by exposing hDATexpressing oocytes to different concentrations of drug and Fig. 3 Dose-response curves (±SEM) for S-methamphetamine (S-METH; triangles), S-methcathinone (S-MCAT; squares), and mephedrone (MEPH; circles) in hDAT at −60 mV. Data points were obtained by exposing hDAT-expressing oocytes to different concentrations of drug for 1 min and measuring peak currents (n=5 to 9 at each concentration). Drug responses are expressed as a percentile of DA pre-pulse peak current (100 %) in each experiment Fig. 4 Application of different concentrations of MDPV or cocaine (COC) to hDAT-expressing Xenopus oocytes voltage clamped at −60 mV (n = 5 to 6 at each concentration). Drug responses are expressed as a percentile of DA pre-pulse peak current (100 %) in each experiment measuring the relative return 60 s after test drug was applied (n≥5 at each concentration).
Discussion
Although both can be classified as phenylpropanonamines, mephedrone and MDPV behaved very differently at hDAT. Mephedrone produced a signature depolarizing current similar to other dopamine releasing agents with a potency similar to S-methamphetamine but several times less than that of S-methcathinone; however, whereas the efficacy of mephedrone is nearly comparable to that of S-methcathinone, it was only about half that of S-methamphetamine. In contrast, MDPV behaved more as a cocaine-like dopamine reuptake inhibitor. That is, rather than the depolarizing effect produced by methamphetamine, methcathinone or mephedrone, MDPV elicited a hyperpolarizing current as seen with cocaine.
The findings of the present investigation can be compared with those of several recent studies. Repeated s.c. injection of (10 and 25 mg/kg) of mephedrone to rats produced a rapid decrease in striatal dopamine, whereas application of a 5 μM concentration of mephedrone caused release of dopamine from rat striatal synaptosomal suspensions (Hadlock et al. 2011) . In another synaptosomal assay, mephedrone was found to inhibit dopamine uptake from rat cortex and striatum, and that it binds in the low micromolar range at the rat dopamine transporter labeled with [ 3 H] WIN35428 (Martínez-Clemente et al. 2012) . Mephedrone (3 mg/kg; s.c.) also caused a rapid increase in extracellular dopamine in rat nucleus accumbens as measured using microdialysis sampling techniques and was suggested to act primarily as a dopamine releasing agent (Kehr et al. 2011) . While this manuscript was being prepared, Baumann et al. (2012) reported that mephedrone is a nonselective substrate for plasma membrane monoamine transporters. Even though mephedrone was not without effect at the serotonin transporter in each of the above studies, it is Fig. 5 Application of Smethamphetamine (S-METH) or mephedrone (MEPH) (10 μM) followed by application of either cocaine (COC) (a, b) or MDPV (c) (10 μM) to hDAT-expressing Xenopus oocytes voltage clamped at −60 mV. All traces are normalized to the S-METH peak current for comparison b Raw traces for MDPV dose-inhibition under the same oocyte conditions as a. Unlike COC, MDPV inhibition did not reach a steady state level within 1 min. The inhibitory effect at all MDPV concentrations persisted until maximum inhibition is reached (for the lowest concentrations, 0.5 μM, it takes more than 5 min to reach steady state; in contrast, the highest concentration of MDPV (10 μM) reaches the steady state in 15 s). c Cumulative data from a (±SEM) for cocaine. Each drug concentration was applied in the presence of dopamine (5 μM). Data were obtained by exposing hDAT-expressing oocytes to different concentrations of drug and measuring the relative return to the baseline 60 s after test drug was applied (n=5 to 9 at each concentration). A similar curve for MDPV was unattainable because at the low concentrations 0.5 and 1.0 μM steady state currents were not reached evident from these and the present findings that mephedrone potently influences dopaminergic function. In agreement with these observations are the results of several rat studies showing that mephedrone is self-administered (Hadlock et al. 2011) , produces an increase in rat body temperature (Baumann et al. 2012; Hadlock et al. 2011) , and is a locomotor stimulant (Baumann et al. 2012; Kehr et al. 2011) .
In contrast, MDPV behaves similar to a cocaine-like dopamine reuptake inhibitor. This is not inconsistent with what is known about bupropion and structurally related aminophenones, some of which behave as dopamine reuptake inhibitors (Meltzer et al. 2006) . Like cocaine, MDPV was able to reverse the current produced by mephedrone when applied in succession. The present findings suggest that the combination of mephedrone and MDPV, as found in bath salts, might alter each other's behavioral effects. However, until their pharmacokinetic properties have been further investigated, it might be speculated that MDPV potentially blocks the reuptake of the dopamine that is initially released by mephedrone leading to a likely additive or synergistic effect. [It might be noted that while this manuscript was under review, Simmler et al. (2012) also found that MDPV does not produce dopamine efflux but behaves as an uptake inhibitor using transporter-transfected HEK-293 cells.] Alternatively, if MDPV has a faster onset of action than mephedrone, the major effect of bath salts might be due primarily to the actions of MDPV. This is currently under investigation.
